Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ANVS
Strong SellSinkerAnnovis Bio, Inc. · Healthcare · United States · $73M · Avg Vol: $1M/d
COMPANY DESCRIPTION
Annovis Bio, Inc. is a clinical-stage drug platform company developing novel therapies to treat neurodegenerative diseases such as Alzheimer's and Parkinson's. The company's competitive moat is its lead compound, buntanetap, which targets multiple neurotoxic proteins simultaneously to restore axonal transport. It operates as a specialized biotechnology player focused on disease-modifying neuroprotective treatments.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -0.59 | -1.54 | -0.67 | -1.40 | — | -1.75 | -1.45 | -0.86 | — |
| Shares | 42.5M | 42.5M | 42.5M | 27.2M | -36.1% | — | — | — | — |
| Debt | — | — | — | — | — | — | — | — | — |
| Equity | 28.3M | -7.8M | 9.3M | 16.9M | -15.9% | — | — | — | — |
| Op CF | -17.3M | -40.0M | -21.9M | -25.6M | — | -43.3M | — | — | — |
| Inv CF | — | — | — | — | — | — | — | — | — |
| Fin CF | 4.6K | 17.3M | 26.7M | 34.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ANVS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ANVS | Annovis Bio, Inc.(you) | $73M | 12 | Strong Sell |
| PLRX | Pliant Therapeutics, Inc. | $69M | 12 | Strong Sell |
| TENX | Tenax Therapeutics, Inc. | $80M | 12 | Strong Sell |
| MAIA | MAIA Biotechnology, Inc. | $81M | 11 | Strong Sell |
| TELO | Telomir Pharmaceuticals, Inc. | $78M | 13 | Strong Sell |
| HYFT | MindWalk Holdings Corp. | $65M | 14 | Strong Sell |
| OSTX | OS Therapies Incorporated | $76M | 15 | Strong Sell |
| CRDF | Cardiff Oncology, Inc. | $73M | 7 | Strong Sell |
| GANX | Gain Therapeutics, Inc. | $77M | 7 | Strong Sell |
| SER | Serina Therapeutics, Inc. | $62M | 14 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%